Table 1.
Pharmacokinetic of some protease inhibitors in the presence of ritonavir in non-COVID-19 patients: effect of sex.
| Drug | Pharmacokinetic Parameters | Men vs. Women | References |
|---|---|---|---|
| Saquinavir | AUC 0–12h Cmin |
25% higher in women 3-fold higher in women |
[86] |
| AUC 0–24h, Cmin, Cmax | Higher in women | [87] | |
| AUC 0–24h Cmin, Cmax, CL |
Higher in women NS |
[88] |
|
| AUC 0–12h, Cmin, Cmax, | Higher in women with low significance | [89] | |
| AUC 0–24h, Cmax, | Higher in women | [90] | |
| Ritonavir | AUC 0–24h, Cmax, Cmin, CL AUC, Cmax Median apparent oral CL |
NS Higher in women Lower in women |
[88] [91] |
| AUC0–12h, Cmax | Higher in women | [87] | |
| AUC 0–24h, Cmax, | Higher in women | [90] | |
| Indinavir | CL, Cmin (after correction for deviation from 70 kg of body weight) |
Lower in women Lower in women |
[92] |
| Lopinavir | AUC 0–12h, Cmin, Cmax | NS | [87] |
| Atazanavir | AUC 24h, Cmax CL |
NS Lower in women |
[90] [93] |
| Darunavir | AUC 12h | NS | [94] |
AUC: area under the curve; CL: clearance; Cmin: the minimum blood plasma concentration reached by a drug before administration of a second dose; Cmax: the maximum (or peak) serum or plasma concentration that a drug achieves; NS: not significant.